Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2021 Earnings Conference Call May 10, 2021 8:00 AM ET Company Participants Mark Jacobson - Chief Operating Officer Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Lori Englebert - Senior Vice President, Commercial and Business Development Cedric O'Gorman - Senior Vice President, Medical Affairs Amanda Jones - Senior Vice President, Clinical Development Conference Call Participants Charles Duncan - Cantor Fitzgerald Joon Lee - Truist ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2020 Earnings Conference Call March 1, 2020 8:00 AM ET Company Participants Mark Jacobson - Chief Operating Officer Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Lori Englebert - Senior Vice President, Commercial and Business Development Cedric O'Gorman - Senior Vice President, Medical Affairs Dr. Amanda Jones - Senior Vice President, Clinical Development Conference Call Participants Charles Duncan - Cantor Fitzgerald Marc Goodman ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45- ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2020 Results Earnings Conference Call November 5, 2020 8:00 AM ET Company Participants Mark Jacobson - Chief Operating Officer Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Lori Englebert - Senior Vice President, Commercial and Business Development Cedric O'Gorman - Senior Vice President, Clinical Development & Medical Affairs Conference Call Participants Charles Duncan - Cantor Fitzgerald Marc Goodman - SVB Leerink Yatin Suneja - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45-42419 ...